Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by PLA2G7 is a secreted enzyme that catalyzes the degradation of platelet-activating factor to biologically inactive products. Additionally we are shipping PLA2G7 Kits (7) and PLA2G7 Proteins (2) and many more products for this protein.
Showing 10 out of 14 products:
Human Polyclonal PLA2G7 Primary Antibody for IF (p), IHC (p) - ABIN686722
Rosing, Fobker, Kannenberg, Gunia, DellAquila, Kwiecien, Stypmann, Nofer: Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. in Atherosclerosis 2013
Show all 2 references for ABIN686722
These findings suggest that plasma PAF (show KIAA0101 Antibodies) may be a potential biomarker for predicting poor bone health in postmenopausal women.
Studied whether the level of Lp-PLA2 (show Lp-PLA2 Antibodies) is associated with subclinical atherosclerosis in patients with rheumatoid arthritis.
Higher Lp-PLA2 (show Lp-PLA2 Antibodies) mass and activity were associated with development of both incident clinical peripheral arterial disease and low ankle brachial index.
A V279F loss-of-function variant in the PLA2G7 (show Lp-PLA2 Antibodies) gene resulting in 50% lower activity for each copy of the variant, is common in East Asians and associated with risk of Vascular diseases.
It is assumed that Lp-PLA2 (show Lp-PLA2 Antibodies) is involved in vascular calcification and that dp-ucMGP is a more appropriate biomarker of residual risk than Lp-PLA2 (show Lp-PLA2 Antibodies) itself.
Cytosolic phospholipase A2 (show PLA2G4A Antibodies) modulates TLR2 (show TLR2 Antibodies) signaling in synoviocytes.
Lipoprotein associated phospholipase A2 activity and apolipoprotein C3 (show APOC3 Antibodies) loss-of-function variants are involved in cardiovascular disease
The study indicated that the A379V variant in PLA2G7 gene might contribute to ischemic stroke susceptibility in northern Chinese Han population.
The presence of subclinical coronary atherosclerosis is associated independently with Lp-PLA2 (show Lp-PLA2 Antibodies), and it has potential utility as a novel indicator of cardiovascular disease risk in the young adult population.
In multi-ethnic cohort, Lp-PLA2 (show Lp-PLA2 Antibodies) was positively associated with CVD risk, regardless of the presence of coronary artery calcium or a thickened carotid-intimal media.
The protein encoded by this gene is a secreted enzyme that catalyzes the degradation of platelet-activating factor to biologically inactive products. Defects in this gene are a cause of platelet-activating factor acetylhydrolase deficiency. Two transcript variants encoding the same protein have been found for this gene.
, 2-acetyl-1-alkylglycerophosphocholine esterase
, LDL-associated phospholipase A2
, PAF 2-acylhydrolase
, PAF acetylhydrolase
, platelet-activating factor acetylhydrolase
, plasma PAF acetylhydrolase
, group-VIIA phospholipase A2
, lipoprotein-associated phospholipase A2